Compare Neurocrine Biosciences Inc (NBIX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs GeneDx Holdings Corp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Neurocrine Biosciences Inc is far larger — about 9.7× GeneDx Holdings Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| NBIX | WGS | |
|---|---|---|
Market Cap | $17.40B | $1.80B |
Sector | Health | Technology |
52-Week High | $180.55 | $167.51 |
52-Week Low | $123.10 | $34.51 |
Enterprise Value | $16.49B | $1.80B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
